TABLE OF CONTENTS
1 INTRODUCTION 211
1.1 OBJECTIVES OF THE STUDY 211
1.2 MARKET DEFINITION 211
1.3 OVERVIEW OF THE EUROPE FAT REDUCTION MARKET 211
1.4 CURRENCY AND PRICING 213
1.5 LIMITATIONS 213
1.6 MARKETS COVERED 214
2 MARKET SEGMENTATION 219
2.1 MARKETS COVERED 219
2.2 GEOGRAPHICAL SCOPE 220
2.3 YEARS CONSIDERED FOR THE STUDY 221
2.4 DBMR TRIPOD DATA VALIDATION MODEL 222
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 225
2.6 MULTIVARIATE MODELLING 226
2.7 TYPE LIFELINE CURVE 226
2.8 DBMR MARKET POSITION GRID 227
2.9 VENDOR SHARE ANALYSIS 228
2.10 MARKET APPLICATION COVERAGE GRID 229
2.11 SECONDARY SOURCES 230
2.12 ASSUMPTIONS 230
3 EXECUTIVE SUMMARY 231
4 PREMIUM INSIGHT 234
4.1 PESTEL ANALYSIS 235
4.2 PORTERS FIVE FORCES 236
4.3 MARKET ANALYSIS 237
4.4 EUROPE (PRICING AND PROCEDURE ANALYSIS) 238
4.4.1 GERMANY 238
4.4.2 TURKEY 239
4.4.3 ITALY 240
4.4.4 POLAND 241
4.4.5 SPAIN 242
4.4.6 RUSSIA 243
4.4.7 FRANCE 244
4.4.8 NETHERLANDS 245
4.4.9 SWITZERLAND 246
4.4.10 BELIGUM 247
4.4.11 AUSTRIA 248
4.4.12 NORWAY 249
4.4.13 IRELAND 250
4.4.14 HUNGARY 251
4.4.15 LITHUAMIA 252
4.4.16 AZERBAIJAN 253
4.4.17 U.K. 254
4.4.18 GEORGIA 255
4.4.19 UKRAINE 256
4.5 BRAND ANALYSIS 257
4.5.1 KYBELLA 257
4.5.2 AQUALYX 258
4.6 PRICING ANALYSIS (USD) 259
4.6.1 EUROPE 259
4.6.1.1 GERMANY 259
4.6.1.2 TURKEY 259
4.6.1.3 ITALY 259
4.6.1.4 POLAND 260
4.6.1.5 SPAIN 260
4.6.1.6 RUSSIA 260
4.6.1.7 FRANCE 261
4.6.1.8 NETHERLANDS 261
4.6.1.9 SWITZERLAND 261
4.6.1.10 BELIGUM 262
4.6.1.11 AUSTRIA 262
4.6.1.12 NORWAY 262
4.6.1.13 IRELAND 263
4.6.1.14 HUNGARY 263
4.6.1.15 LITHUAMIA 263
4.6.1.16 AZERBAIJAN 264
4.6.1.17 U.K. 264
4.6.1.18 GEORGIA 264
4.6.1.19 UKRAINE 265
4.7 PATENT ANALYSIS OF THE EUROPE FAT REDUCTION MARKET 266
4.7.1 EUROPE 266
4.7.1.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 266
4.7.1.2 SYNTHESIS OF DEOXYCHOLIC ACID (DCA) 267
4.7.1.3 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT 268
4.7.1.4 METHOD AND COMPOSITION FOR REDUCING SUBCUTANEOUS FAT DEPOSITS 269
4.7.2 HUNGARY 270
4.7.2.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 270
4.8 PRICING ANALYSIS (USD) 271
4.8.1 KYBELLA 271
4.8.2 COOLSCULPTING 273
4.8.3 COOLSCULPTING ELITE 275
4.8.4 COOLTONE 277
5 INDUSTRY INSIGHTS: 280
5.1 DEMOGRAPHIC TRENDS: 281
5.2 CONCLUSION: 282
6 EUROPE FAT REDUCTION MARKET, REGULATIONS 283
6.1 DOMINICAN REPUBLIC 283
6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 283
6.1.2 RENEWAL OF REGISTRATION IS REQUIRED IF THERE IS A CHANGE IN PRODUCT FORMULATION OR A CHANGE IN THE SITE OF MANUFACTURE. 284
6.1.3 TIMELINE 284
6.2 GUATEMALA 285
6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 285
6.2.2 REGULATORY APPROVAL AGENCIES 285
6.2.3 LICENSING AND REGISTRATION 286
6.2.4 POST-MARKETING SURVEILLANCE 286
6.2.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 286
6.3 HONDURAS 286
6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 286
6.3.2 REGULATORY APPROVAL AGENCIES 286
6.4 NICARAGUA 287
6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 287
6.4.2 LICENSING AND REGISTRATION 287
6.4.3 POST-MARKETING SURVEILLANCE 287
6.5 GERMANY 287
6.5.1 REGULATORY APPROVAL AGENCIES AND PROCESS 287
6.6 FRANCE 288
6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 288
6.6.2 REGULATORY APPROVAL AGENCIES 288
6.6.3 POST-MARKETING SURVEILLANCE 288
6.7 U.K. 288
6.7.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 288
6.7.2 GENERIC MARKET 289
6.7.3 REGULATORY APPROVAL AGENCIES 289
6.7.4 LICENSING AND REGISTRATION 290
6.7.5 POST-MARKETING SURVEILLANCE 291
6.8 ITALY 291
6.8.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 291
6.8.2 REGULATORY APPROVAL AGENCIES 291
6.8.3 LICENSING AND REGISTRATION 292
6.8.4 POST-MARKETING SURVEILLANCE 292
6.8.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 292
6.9 SPAIN 292
6.9.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 292
6.9.2 REGULATORY APPROVAL AGENCIES 292
6.9.3 LICENSING AND REGISTRATION 292
6.10 RUSSIA 293
6.10.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 293
6.10.2 TIMELINE 293
6.10.3 REGULATORY APPROVAL AGENCIES 293
6.10.4 LICENSING AND REGISTRATION 293
6.10.5 GOOD MANUFACTURING PRACTICES 294
6.10.6 TIMELINES FOR RUSSIAN GMP CERTIFICATE 294
6.11 TURKEY 295
6.11.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 295
6.11.2 REGULATORY APPROVAL AGENCIES 295
6.11.3 LICENSING AND REGISTRATION 295
6.11.4 POST-MARKETING SURVEILLANCE 296
6.11.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 296
6.12 AZERBAIJAN 296
6.12.1 THE FOLLOWING TERMS ARE USED IN THE PRESENT REGULATIONS: 296
6.12.2 PROCEDURE OF SUBMITTING FOR STATE REGISTRATION 297
6.12.3 LICENSING 298
6.13 UKRAINE 298
6.13.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 298
6.13.2 REGULATORY APPROVAL AGENCIES 298
6.13.3 LICENSING AND REGISTRATION 299
6.13.4 POST-MARKETING SURVEILLANCE 300
6.14 BELGIUM 301
6.14.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 301
6.14.2 REGULATORY APPROVAL AGENCIES 301
6.14.3 LICENSING AND REGISTRATION 301
6.15 HUNGARY 301
6.15.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 301
6.15.2 REGULATORY APPROVAL AGENCIES 301
6.15.3 LICENSING AND REGISTRATION 302
6.15.4 POST-MARKETING SURVEILLANCE 302
6.16 LITHUANIA 302
6.16.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 302
6.16.2 REGULATORY APPROVAL AGENCIES 303
6.17 AUSTRIA 303
6.17.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 303
6.17.2 REGULATORY APPROVAL AGENCIES 303
6.17.3 LICENSING AND REGISTRATION 303
6.17.4 POST-MARKETING SURVEILLANCE 303
6.18 IRELAND 304
6.18.1 REGULATORY APPROVAL AGENCIES 304
6.19 NORWAY 305
6.19.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 305
6.20 NETHERLANDS 306
6.20.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 306
6.21 SWITZERLAND 306
6.21.1 REGULATORY APPROVAL AGENCIES AND APPROVAL PROCESS 306
7 PIPELINE ANALYSIS OF THE EUROPE FAT REDUCTION MARKET 307
8 MARKET ACCESS 314
8.1 MANUFACTURER AND STRATEGIC DEALS 314
8.2 CURRENT TREATMENT PRACTICES 314
8.3 IMPACT OF UPCOMING THERAPY 315
9 MARKET OVERVIEW 316
9.1 DRIVERS 318
9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 318
9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 319
9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 320
9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 321
9.2 RESTRAINTS 322
9.2.1 HIGH COST OF PROCEDURES 322
9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 323
9.2.3 PRODUCT RECALL 323
9.3 OPPORTUNITIES 324
9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 324
9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 325
9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 327
9.4 CHALLENGES 329
9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 329
9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 329
10 EUROPE FAT REDUCTION MARKET, BY TYPE 331
10.1 OVERVIEW 332
10.2 SURGICAL FAT REDUCTION 335
10.2.1 LIPOSUCTION 336
10.2.1.1 BY TYPE 337
10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 337
10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 338
10.2.1.1.3 TUMESCENT LIPOSUCTION 338
10.2.1.1.4 SUPER-WET TECHNIQUE 338
10.2.1.2 BY APPLICATION 338
10.2.1.2.1 ABDOMINAL FAT 339
10.2.1.2.2 THIGHS FAT 339
10.2.1.2.3 BUTTOCK FAT 339
10.2.1.2.4 UPPER-ARM FAT 339
10.2.1.2.5 FACIAL FAT-DEPOSITS 339
10.2.1.2.5.1 SUBMENTAL AREAS 340
10.2.1.2.5.2 MALAR 340
10.2.1.2.5.3 MANDIBULAR 340
10.2.1.2.6 KNEE FAT 340
10.2.2 SURGICAL REJUVENATION 340
10.2.2.1 FACE LIFT 341
10.2.2.2 NECK LIFT 341
10.2.3 CHIN IMPLANT 341
10.2.3.1 SILICONE CHIN IMPLANTS 342
10.2.3.2 OTHERS 342
10.2.4 PORUS IMPLANTS 342
10.2.4.1 TEFLON 343
10.2.4.2 GORE-TEX 343
10.2.4.3 MEDPORE IMPLANTS 343
10.3 NON-INVASIVE FAT REDUCTION 343
10.3.1 CRYOLIPOLYSIS 346
10.3.1.1 COOL SCULPTING 346
10.3.1.2 COOL SCULPTING ELITE 346
10.3.1.3 COOL TONE 347
10.3.1.4 OTHERS 347
10.3.1.4.1 ABDOMINAL FAT 347
10.3.1.4.2 THIGHS FAT 347
10.3.1.4.3 BUTTOCK FAT 348
10.3.1.4.4 UPPER-ARM FAT 348
10.3.1.4.5 FACIAL FAT-DEPOSITS 348
10.3.1.4.6 KNEE FAT 348
10.3.2 ULTRASOUND 348
10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 349
10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 349
10.3.2.2.1 ABDOMINAL FAT 350
10.3.2.2.2 THIGHS FAT 350
10.3.2.2.3 BUTTOCK FAT 350
10.3.2.2.4 UPPER-ARM FAT 350
10.3.2.2.5 FACIAL FAT-DEPOSITS 350
10.3.2.2.6 KNEE FAT 350
10.3.3 RADIOFREQUENCY 351
10.3.3.1 ABDOMINAL FAT 351
10.3.3.2 THIGHS FAT 351
10.3.3.3 BUTTOCK FAT 351
10.3.3.4 UPPER-ARM FAT 351
10.3.3.5 FACIAL FAT-DEPOSITS 352
10.3.3.6 KNEE FAT 352

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.